sulfamethoxazole 40 MG/ML / trimethoprim 8 MG/ML Oral Suspension

What the CMS Formulary Data Shows for sulfamethoxazole 40 MG/ML / trimethoprim 8 MG/ML Oral Suspension

Per the CMS 2026 Part D formulary file, sulfamethoxazole 40 MG/ML / trimethoprim 8 MG/ML Oral Suspension (RxNorm concept RXCUI 313134, generic name sulfamethoxazole) appears on 329 distinct formulary files spanning 5,061 Medicare Part D plan offerings - 99.9% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.3.

Real-world access to sulfamethoxazole 40 MG/ML / trimethoprim 8 MG/ML Oral Suspension depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 3,086,523 Part D beneficiaries filled sulfamethoxazole 40 MG/ML / trimethoprim 8 MG/ML Oral Suspension in 2023, with total plan-and-beneficiary spending of $28,506,828 and an average per-beneficiary annual cost of $9.24. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry sulfamethoxazole 40 MG/ML / trimethoprim 8 MG/ML Oral Suspension today.